抗T淋巴细胞球蛋白治疗包涵体肌炎：一项随机试验性研究。
Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.
作者信息
Lindberg C, Trysberg E, Tarkowski A, Oldfors A
机构信息
Department of Neurology, Sahlgrenska University Hospital/Molndal, Sahlgrenska NeuroMuscular Center, Gothenburg, Sweden.
出版信息
Neurology. 2003 Jul 22;61(2):260-2. doi: 10.1212/01.wnl.0000071852.27182.c7.
The authors performed an open, randomized trial in patients with inclusion body myositis comparing 1) 12-month treatment with oral methotrexate 7.5 mg/week alone (MTX group) with 2) 12-month MTX treatment preceded by 7 days of IV anti-T-lymphocyte immunoglobulin treatment (ATG group). Eleven patients were randomized; 10 patients completed 12 months follow-up. Myometry showed that patients in the ATG group (n = 6) increased in mean muscle strength by 1.4% compared with the MTX group (n = 5), whose muscle strength decreased by 11.1% (p = 0.021).
作者对包涵体肌炎患者进行了一项开放性随机试验，比较：1）单独使用口服甲氨蝶呤7.5毫克/周进行12个月治疗（甲氨蝶呤组）与2）在静脉注射抗T淋巴细胞免疫球蛋白治疗7天后进行12个月的甲氨蝶呤治疗（抗胸腺细胞球蛋白组）。11名患者被随机分组；10名患者完成了12个月的随访。肌功能测量显示，抗胸腺细胞球蛋白组（n = 6）的患者平均肌肉力量增加了1.4%，而甲氨蝶呤组（n = 5）的肌肉力量下降了11.1%（p = 0.021）。
Zotero 插件